Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown FH535 hepatocellular carcinoma not applicable detail...
MET over exp Tepotinib hepatocellular carcinoma sensitive detail...
Unknown unknown Fluorouracil + Interferon alpha-2b hepatocellular carcinoma not applicable detail...
Unknown unknown Linifanib hepatocellular carcinoma not applicable detail...
Unknown unknown Sorafenib hepatocellular carcinoma not applicable detail...
KRAS mutant Refametinib + Sorafenib hepatocellular carcinoma sensitive detail...
Unknown unknown Torin 2 hepatocellular carcinoma not applicable detail...
MET act mut Tepotinib hepatocellular carcinoma sensitive detail...
CTNNB1 mutant PMED-1 hepatocellular carcinoma sensitive detail...
Unknown unknown LCL161 + Paclitaxel hepatocellular carcinoma not applicable detail...
Unknown unknown Fingolimod + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown PI-88 hepatocellular carcinoma not applicable detail...
Unknown unknown Lenvatinib hepatocellular carcinoma not applicable detail...
Unknown unknown NanoHHI hepatocellular carcinoma not applicable detail...
Unknown unknown OPB-31121 hepatocellular carcinoma no benefit detail...
Unknown unknown YW3-56 hepatocellular carcinoma not applicable detail...
Unknown unknown PF-03446962 hepatocellular carcinoma not applicable detail...
Unknown unknown NSC156529 hepatocellular carcinoma not applicable detail...
BCORL1 over exp N/A hepatocellular carcinoma not applicable detail...
Unknown unknown 17-Demethoxy-reblastatin hepatocellular carcinoma not applicable detail...
Unknown unknown Refametinib + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Resminostat + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Domatinostat hepatocellular carcinoma not applicable detail...
MET amp AMG 337 hepatocellular carcinoma sensitive detail...
Unknown unknown Lenalidomide + Sorafenib hepatocellular carcinoma no benefit detail...
Unknown unknown Codrituzumab hepatocellular carcinoma no benefit detail...
Unknown unknown Brivanib hepatocellular carcinoma no benefit detail...
Unknown unknown Ramucirumab hepatocellular carcinoma not applicable detail...
Unknown unknown Selumetinib + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Erlotinib + Sorafenib hepatocellular carcinoma no benefit detail...
TP53 Y220C CP-31398 hepatocellular carcinoma sensitive detail...
TP53 R249S CP-31398 hepatocellular carcinoma sensitive detail...
FGFR1 pos FGFR2 pos AZD4547 hepatocellular carcinoma sensitive detail...
FGFR1 pos FGFR2 pos PHA-665752 hepatocellular carcinoma no benefit detail...
Unknown unknown SF1126 hepatocellular carcinoma not applicable detail...
Unknown unknown SF1126 + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Metformin + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Cabozantinib + CT-707 hepatocellular carcinoma not applicable detail...
Unknown unknown CT-707 + PHA-665752 hepatocellular carcinoma not applicable detail...
Unknown unknown Regorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Droxinostat hepatocellular carcinoma not applicable detail...
Unknown unknown Chiauranib hepatocellular carcinoma not applicable detail...
Unknown unknown PEGPH20 hepatocellular carcinoma not applicable detail...
Unknown unknown Riluzole hepatocellular carcinoma not applicable detail...
Unknown unknown Foretinib hepatocellular carcinoma not applicable detail...
Unknown unknown RU-A1 hepatocellular carcinoma not applicable detail...
Unknown unknown Fluorouracil + RU-A1 hepatocellular carcinoma not applicable detail...
Unknown unknown Nivolumab hepatocellular carcinoma not applicable detail...
Unknown unknown CEBPA-51 hepatocellular carcinoma not applicable detail...
Unknown unknown SGI-1027 hepatocellular carcinoma not applicable detail...
Unknown unknown KU-0063794 hepatocellular carcinoma not applicable detail...
MET over exp SCC244 hepatocellular carcinoma sensitive detail...
Unknown unknown Camrelizumab hepatocellular carcinoma not applicable detail...
Unknown unknown GNS561 hepatocellular carcinoma not applicable detail...
Unknown unknown Bevacizumab + MINT1526A hepatocellular carcinoma not applicable detail...
NRAS mutant Refametinib + Sorafenib hepatocellular carcinoma sensitive detail...
Unknown unknown Pembrolizumab hepatocellular carcinoma not applicable detail...
Unknown unknown Cabozantinib hepatocellular carcinoma not applicable detail...
MET over exp Tivantinib hepatocellular carcinoma no benefit detail...
Unknown unknown Apatinib + Camrelizumab hepatocellular carcinoma not applicable detail...
PTEN mutant Sorafenib hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified PD-1 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified PD-L1 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified CTLA4 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified CTLA4 antibody + unspecified PD-1 antibody hepatocellular carcinoma decreased response detail...
Unknown unknown Orlistat hepatocellular carcinoma not applicable detail...
Unknown unknown Orlistat + Paclitaxel hepatocellular carcinoma not applicable detail...
MET amp TPX-0022 hepatocellular carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00986661 Phase I PV-10 A Study to Assess PV-10 Chemoablation of Cancer of the Liver Recruiting
NCT01015833 Phase III Doxorubicin Sorafenib Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Active, not recruiting
NCT01075113 Phase I Sorafenib + Vorinostat Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer Active, not recruiting
NCT01141478 Phase I Sorafenib Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria Unknown status
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01177397 Phase Ib/II CC-223 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01246986 Phase II Galunisertib + Sorafenib Galunisertib A Study of LY2157299 in Participants With Hepatocellular Carcinoma Active, not recruiting
NCT01306058 Phase Ib/II Carotuximab + Sorafenib Sorafenib and TRC105 in Hepatocellular Cancer Completed
NCT01356628 Phase II Palbociclib A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer Active, not recruiting
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting
NCT01556490 Phase III Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Active, not recruiting
NCT01567930 Phase II Temsirolimus Temsirolimus as Second-line Therapy in HCC Unknown status
NCT01624285 Phase II Sorafenib Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer Active, not recruiting
NCT01628640 Phase I VSV-IFN-beta Viral Therapy in Treating Patient With Liver Cancer Active, not recruiting
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Recruiting
NCT01655693 Phase III Doxorubicin Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive) Active, not recruiting
NCT01658878 Phase I Nivolumab Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma) Active, not recruiting
NCT01666756 Phase I KD018 + Sorafenib Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Active, not recruiting
NCT01687673 Phase II Sorafenib + Temsirolimus Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Active, not recruiting
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed
NCT01730937 Phase III Sorafenib Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Recruiting
NCT01754987 Phase Ib/II Sorafenib A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Completed
NCT01755767 Phase III Tivantinib Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy Completed
NCT01761266 Phase III Lenvatinib Sorafenib A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma Active, not recruiting
NCT01774344 Phase III Regorafenib Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE) Active, not recruiting
NCT01775501 Phase II Sorafenib Fluorouracil Oxaliplatin Leucovorin Sorafenib + mFOLFOX for Hepatocellular Carcinoma Active, not recruiting
NCT01801163 Phase I Sorafenib A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) Withdrawn
NCT01835223 Phase Ib/II Tivozanib Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT01840592 Phase II Doxorubicin + Sorafenib Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib Active, not recruiting
NCT01849588 FDA approved Sorafenib Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C Terminated
NCT01853618 Phase I Tremelimumab Tremelimumab With Chemoembolization or Ablation for Liver Cancer Active, not recruiting
NCT01887717 Phase III Sorafenib Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein Terminated
NCT01900002 Phase II Sorafenib Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting
NCT01908426 Phase III Cabozantinib Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Active, not recruiting
NCT01915602 Phase II Refametinib + Sorafenib Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) Completed
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed
NCT02024087 Phase Ib/II Dalantercept + Sorafenib Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Active, not recruiting
NCT02069145 Phase I Ipafricept + Sorafenib Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Completed
NCT02072486 Phase I Sorafenib Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT02081755 Tacrolimus Everolimus Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer Recruiting
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed
NCT02101593 Phase I ADI-PEG 20 Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer Completed
NCT02128958 Phase II CF102 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Active, not recruiting
NCT02143401 Phase I Navitoclax + Sorafenib Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Recruiting
NCT02151864 Phase I Sonidegib LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis Completed
NCT02174549 Phase I tirapazamine Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Active, not recruiting
NCT02227914 Phase Ib/II Oprozomib Sorafenib Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Withdrawn
NCT02232633 Phase II BBI503 A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer Active, not recruiting
NCT02279719 Phase Ib/II Sorafenib BBI503 + Sorafenib Napabucasin + Sorafenib A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma Active, not recruiting
NCT02288507 Phase I Sorafenib Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer Withdrawn
NCT02292173 Phase I Sorafenib + Trametinib Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer Active, not recruiting
NCT02314052 Phase Ib/II DCR-MYC Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma Terminated
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02323906 Phase Ib/II CC-122 + Sorafenib Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer Terminated
NCT02406508 Phase II Melphalan Sorafenib Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Withdrawn
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Active, not recruiting
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02435433 Phase III Ramucirumab A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) Recruiting
NCT02460991 Phase I Sorafenib Doxorubicin A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma Terminated
NCT02508467 Phase I BLU-554 A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma Recruiting
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02519348 Phase II Tremelimumab Durvalumab A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma Recruiting
NCT02524119 Phase II Ribociclib LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001) Recruiting
NCT02528643 Phase II Enzalutamide A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Active, not recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02560779 Phase Ib/II Carotuximab + Sorafenib Trial of TRC105 and Sorafenib in Patients With HCC Active, not recruiting
NCT02562755 Phase III JX-594 Sorafenib Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Recruiting
NCT02564614 Phase I EZN-2968 A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) Completed
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Active, not recruiting
NCT02575339 Phase Ib/II Sorafenib Sapanisertib MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Active, not recruiting
NCT02576509 Phase III Nivolumab Sorafenib A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting
NCT02597036 Phase I LY3127804 Ramucirumab A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Active, not recruiting
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated
NCT02642913 Phase Ib/II Enzalutamide Sorafenib Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients Active, not recruiting
NCT02658019 Phase II Pembrolizumab Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma Active, not recruiting
NCT02675946 Phase I CGX1321 Study of CGX1321 in Subjects With Advanced Solid Tumors Recruiting
NCT02702401 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Active, not recruiting
NCT02702414 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Active, not recruiting
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Recruiting
NCT02795429 Phase Ib/II Spartalizumab Capmatinib + Spartalizumab Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC Recruiting
NCT02821754 Phase Ib/II Durvalumab + Tremelimumab A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Recruiting
NCT02834780 Phase I H3B-6527 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Recruiting
NCT02837029 Phase I Nivolumab Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer Recruiting
NCT02842125 Phase I Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Recruiting
NCT02859324 Phase Ib/II CC-122 + Nivolumab A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) Active, not recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02906397 Phase I Galunisertib A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting
NCT02939807 Phase II ABC294640 A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma Recruiting
NCT02940496 Phase Ib/II Pembrolizumab Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Active, not recruiting
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT02988440 Phase I Sorafenib + Spartalizumab Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients Active, not recruiting
NCT02989870 Phase I Bavituximab + Sorafenib Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma Withdrawn
NCT03006926 Phase I Lenvatinib + Pembrolizumab A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma Active, not recruiting
NCT03037437 Phase II Hydroxychloroquine + Sorafenib Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer Recruiting
NCT03059147 Phase I SF1126 A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma Recruiting
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting
NCT03099564 Phase I Pembrolizumab Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Recruiting
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Recruiting
NCT03143270 Phase I Nivolumab A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Recruiting
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Recruiting
NCT03145558 Phase II Doxorubicin tirapazamine TATE Versus TACE in Intermediate Stage HCC (TATE) Recruiting
NCT03203304 Phase I Nivolumab Ipilimumab + Nivolumab Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma Recruiting
NCT03211416 Phase Ib/II Pembrolizumab + Sorafenib Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer Recruiting
NCT03222076 Phase II Ipilimumab + Nivolumab Nivolumab Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Recruiting
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03298451 Phase III Sorafenib Durvalumab + Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Recruiting
NCT03299946 Phase I Cabozantinib + Nivolumab Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) Recruiting
NCT03316222 Phase Ib/II GNS561 Study of GNS561 in Patients With Liver Cancer Recruiting
NCT03316872 Phase II Pembrolizumab Study of Pembrolizumab and Radiotherapy in Liver Cancer Recruiting
NCT03318562 Phase II Tomivosertib A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC Terminated
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Recruiting
NCT03347292 Phase I Pembrolizumab + Regorafenib Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC Recruiting
NCT03382886 Phase I Bevacizumab + Nivolumab Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma (NUANCE) Recruiting
NCT03383458 Phase III Nivolumab A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Recruiting
NCT03412773 Phase III BGB-A317 Sorafenib Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC Recruiting
NCT03419897 Phase II BGB-A317 Study of BGB-A317 in Patients With Previously Treated Unresectable HCC Active, not recruiting
NCT03433703 Phase II Lenvatinib Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) Terminated
NCT03434379 Phase III Atezolizumab + Bevacizumab Sorafenib A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] Recruiting
NCT03439891 Phase II Nivolumab + Sorafenib Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Recruiting
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Recruiting
NCT03482102 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Recruiting
NCT03496051 Phase 0 EZN-2968 Single Patient Access (Compassionate Use) for Continued Treatment of RO7070179 for Adult Subjects With Advanced Hepatocellular Carcinoma (HCC) Available
NCT03511222 Phase I Pembrolizumab + Vorolanib Nivolumab + Vorolanib Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03519997 Phase II Bavituximab + Pembrolizumab A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting
NCT03533582 Phase II Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03539822 Phase I Cabozantinib + Durvalumab Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) Recruiting
NCT03563170 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Sorafenib Sorafenib QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Active, not recruiting
NCT03582618 Phase II CVM-1118 + Sorafenib CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma Recruiting
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Recruiting
NCT03638141 Phase II Durvalumab + Tremelimumab CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Recruiting
NCT03647163 Phase I Pembrolizumab + VSV-hIFNbeta-NIS Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC Recruiting
NCT03655002 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer Recruiting
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting
NCT03680508 Phase II TSR-022 + TSR-042 TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer Not yet recruiting
NCT03684811 Phase Ib/II Cisplatin + FT-2102 + Gemcitabine Azacitidine + FT-2102 FT-2102 FT-2102 + Nivolumab A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Recruiting
NCT03695250 Phase Ib/II BMS-986205 + Nivolumab BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer Recruiting
NCT03713593 Phase III Lenvatinib Lenvatinib + Pembrolizumab Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) Recruiting
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03755791 Phase III Cabozantinib Sorafenib Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) Recruiting
NCT03778957 Phase III Durvalumab Bevacizumab + Durvalumab A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) Recruiting
NCT03781960 Phase II Abemaciclib + Nivolumab Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma Not yet recruiting
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Recruiting
NCT03812562 Phase I Nivolumab Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection Recruiting
NCT03821935 Phase I ABBV-151 ABBV-151 + ABBV-181 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03836352 Phase II DPX-Survivac + Pembrolizumab Cyclophosphamide + DPX-Survivac + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Recruiting
NCT03847428 Phase III Durvalumab Bevacizumab + Durvalumab Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Not yet recruiting
NCT03867084 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) Recruiting
NCT03916627 Phase II Cemiplimab Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC Not yet recruiting
NCT03937830 Phase II Bevacizumab + Doxorubicin + Durvalumab Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma Not yet recruiting